Biovie (BIVI) Net Cash Flow (2013 - 2026)
Biovie (BIVI) posted Net Cash Flow of -$7.4 million for Q1 2026, down 67.69% sequentially from -$4.4 million in Q4 2025, and down 493.67% YoY from $1.9 million in Q1 2025.
Biovie (BIVI) Net Cash Flow (2013 - 2026) Analysis & Trends
Biovie has reported Net Cash Flow for 14 years, with the latest figure at -$7.4 million in Q1 2026.
- Quarterly Net Cash Flow fell 493.67% year-over-year to -$7.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$10.1 million (down 39.66% YoY) and the FY2025 annual result came in at -$6.3 million, down 243.72% from the prior year.
- Net Cash Flow eased to -$7.4 million in Q1 2026 per BIVI's latest filing, from -$4.4 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $24.5 million in Q4 2022 and troughed at -$11.8 million in Q2 2023.
- A 5-year average of $742247.8 and a median of -$2.0 million in 2023 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2022 and 2024: Net Cash Flow tumbled 1021.01% in 2022, then jumped 614.56% in 2024.
- Over 5 years, Net Cash Flow stood at $24.5 million in 2022, then plunged by 104.03% to -$987972.0 in 2023, then surged by 543.55% to $4.4 million in 2024, then sank by 201.27% to -$4.4 million in 2025, then slumped by 67.69% to -$7.4 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$7.4 million, -$4.4 million, and $7.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Biovie | 14.17 Mn | 14.17 Mn | - | -4.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.12 Mn |
| Jun 30, 2026 | -4.12 Mn |
| Mar 31, 2026 | -7.44 Mn |
| Mar 31, 2026 | -7.44 Mn |
| Dec 31, 2025 | -4.44 Mn |
| Dec 31, 2025 | -4.44 Mn |
| Sep 30, 2025 | 7.43 Mn |
| Sep 30, 2025 | 7.43 Mn |
| Jun 30, 2025 | -5.61 Mn |
| Jun 30, 2025 | -5.61 Mn |
| Mar 31, 2025 | -1.25 Mn |
| Mar 31, 2025 | -1.25 Mn |
| Dec 31, 2024 | 4.38 Mn |
| Dec 31, 2024 | 4.38 Mn |
| Sep 30, 2024 | -3.82 Mn |
| Sep 30, 2024 | -3.82 Mn |
| Jun 30, 2024 | -6.51 Mn |
| Jun 30, 2024 | -6.51 Mn |
| Mar 31, 2024 | 10.12 Mn |
| Mar 31, 2024 | 10.12 Mn |